Reports

Ideas That Generate Results

List of Figures:

Figure 3-1: Global - Leading Causes of Non-Communicable Deaths (%), 2008
Figure 3-2: Global - Number of Cancer Deaths (Million), 2002, 2020 & 2030
Figure 3-3: Global - Number of New Cancer Cases (Million), 2009 & 2020
Figure 3-4: Global - New Cancer Cases by Region (%), 2009
Figure 3-5: Global - Forecast for the New Cancer Cases by Region (%), 2020
Figure 4-1: Global - Cancer Market (Billion US$), 2011-2015
Figure 4-2: Global - Cancer Market by Player (%), 2011
Figure 4-3: Global - Cancer Market by Therapeutic Segment (%), 2011
Figure 5-1: Types of Monoclonal Antibodies
Figure 5-2: Hybridoma Technology for Mouse-derived Monoclonal Antibodies
Figure 7-1: Global - Anti-Neoplastic mAbs Market (Billion US$), 2011-2015
Figure 7-2: Global - Anti-Neoplastic mAbs Market by Product (%), 2011
Figure 7-3: Global - Avastin Sales (Billion US$), 2011-2015
Figure 7-4: Global - MabThera/Rituxan Sales (Billion US$), 2011-2015
Figure 7-5: Global - Herceptin Sales (Billion US$), 2011-2015
Figure 7-6: Global - Erbitux Sales (Billion US$), 2011-2015
Figure 7-7: Global - Vectibix Sales (Million US$), 2011-2015
Figure 7-8: Global - Anti-Neoplastic mAbs Market by Country/Region (%), 2011
Figure 7-9: US - Anti-Neoplastic mAbs Market (Billion US$), 2011-2015
Figure 7-10: Japan - Anti-Neoplastic mAbs Market (Billion US$), 2011-2015
Figure 7-11: Europe - Anti-Neoplastic mAbs Market (Billion US$), 2011-2015
Figure 7-12: Global - Anti-Neoplastic mAbs Market by Player (%), 2011
Figure 8-1: Global - Breakup of Anti-Neoplastic mAbs in Pipeline by Phase

List of Tables:

Table 3-1: Global - Number of New Cancer Cases by Type and Geography (2009)
Table 3-2: Global - Forecast for the Number of New Cancer Cases by Type and Geography (2020)
Table 4-1: Global - Revenues from Major Therapy Areas (Billion US$), 2011 & 2015
Table 7-1: Global - List of FDA Approved Anti-Neoplastic mAbs with Year and Indication
Table 7-2: US - Forecast for the Number of Cancer Cases and Deaths by Types (2012)
Table 7-3: US - Anti-Neoplastic mAbs Expenditure in Clinics (Million US$), 2010 & 2011
Table 7-4: Japan - Number of Cancer Deaths by Type and Gender (2008 & 2009)
Table 7-5: Japan - Approval Date for Key Cancer mAbs
Table 7-6: EU - Number of Cancer Cases and Deaths by Type (2008)
Table 7-7: EU - Approval Date for Key Cancer mAbs
Table 8-1: Global - Anti-Neoplastic mAbs of Key Players in Pipeline
Table 8-2: Global - Anti-Neoplastic mAbs in Pipeline for Cancer Type by Rank
Table 9-1: Roche - Key Monoclonal Antibodies in Market
Table 9-2: Roche - Key Monoclonal Antibodies in Pipeline
Table 9-3: Immunomedics - Key Monoclonal Antibodies in Market
Table 9-4: Immunomedics - Key Monoclonal Antibodies in Pipeline
Table 9-5: Bristol-Myers Squibb - Key Monoclonal Antibodies in Market
Table 9-6: Bristol-Myers Squibb - Key Monoclonal Antibodies in Pipeline
Table 9-7: AstraZeneca - Key Monoclonal Antibodies in Pipeline
Table 9-8: Eli Lilly - Key Monoclonal Antibodies in Market
Table 9-9: Eli Lilly - Key Monoclonal Antibodies in Pipeline
Table 9-10: Amgen - Key Monoclonal Antibodies in Market
Table 9-11: Amgen - Key Monoclonal Antibodies in Pipeline